Bioventus Inc. $BVS is Nantahala Capital Management LLC's 8th Largest Position

Key Points

• Nantahala Capital Management LLC increased its stake in Bioventus Inc. by 2.5%, owning approximately 5.03% of the company worth $37.75 million as of its latest filing.
• Several institutional investors, including Invesco Ltd. and Driehaus Capital Management LLC, significantly boosted their stakes in Bioventus during the first quarter.
• Analysts have set a consensus price target of $13.75 for Bioventus shares, indicating a generally positive outlook with multiple "buy" ratings.

Nantahala Capital Management LLC raised its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,125,650 shares of the company's stock after acquiring an additional 98,841 shares during the quarter. Bioventus makes up about 1.5% of Nantahala Capital Management LLC's investment portfolio, making the stock its 8th biggest position. Nantahala Capital Management LLC owned about 5.03% of Bioventus worth $37,750,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Cubist Systematic Strategies LLC raised its holdings in Bioventus by 314.0% during the first quarter. Cubist Systematic Strategies LLC now owns 153,489 shares of the company's stock valued at $1,404,000 after acquiring an additional 116,418 shares during the period. Panagora Asset Management Inc. raised its holdings in Bioventus by 10.3% during the first quarter. Panagora Asset Management Inc. now owns 278,305 shares of the company's stock valued at $2,546,000 after acquiring an additional 25,888 shares during the period. Driehaus Capital Management LLC grew its position in shares of Bioventus by 29.1% during the first quarter. Driehaus Capital Management LLC now owns 1,445,257 shares of the company's stock valued at $13,224,000 after purchasing an additional 325,402 shares in the last quarter. State of Wyoming grew its position in shares of Bioventus by 32.9% during the first quarter. State of Wyoming now owns 26,942 shares of the company's stock valued at $247,000 after purchasing an additional 6,673 shares in the last quarter. Finally, EntryPoint Capital LLC grew its position in shares of Bioventus by 7.8% during the first quarter. EntryPoint Capital LLC now owns 28,371 shares of the company's stock valued at $260,000 after purchasing an additional 2,048 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Bioventus in a research report on Monday, July 7th. They set an "overweight" rating and a $12.00 price objective for the company. Craig Hallum set a $15.00 price objective on Bioventus and gave the company a "buy" rating in a research report on Wednesday, May 7th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $13.75.

Bioventus Trading Up 0.9%

BVS traded up $0.06 on Thursday, hitting $7.10. The company had a trading volume of 179,663 shares, compared to its average volume of 401,751. Bioventus Inc. has a 12-month low of $5.81 and a 12-month high of $14.38. The business's fifty day simple moving average is $6.92 and its 200 day simple moving average is $7.62. The company has a market cap of $587.02 million, a PE ratio of -11.64 and a beta of 0.84. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.